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after treatment with oral isotretinoin for severe acne vulgaris and hidradenitis suppurativa, respec-
tively. IBD may potentially be a serious side effect to oral isotretinoin in dermatology practice.
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Isotretinoin is a vitamin A derivative, and has been used in der-
matology since 1982 for treating severe nodulocystic acne, but
it also has some well known off-label uses (Reddy et al., 2006).
Baseline investigations in the form of liver function tests and li-
pid proﬁles are very important and patients need regular follow
ups. Female patients in the reproductive age require two forms
of contraception prior to using isotretinoin as it is a well known
teratogen, and baseline as well as monthly pregnancy tests are
required (Roaccutane package insert, 2011; Wolverton, 2007).
Isotretinoin is known to cause xerosis of the skin and mucous
membranes as one of its most common side effects, but GIT
side effects in the form of nausea, diarrhea and abdominal pain
are also considered common side effects, although less.O. Box 40011, Al-Khobar
(S. Al-Breiki).
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2011; Wolverton, 2007). The GIT side effects can be potentially
serious as there are reported cases in the literature documenting
serious GIT manifestations namely, IBD ﬂares as well as new
onset IBD. The isotretinoin package insert also mentions
GIT side effects occurring in isotretinoin users in a chance of
less than 1 in 10,000 in which IBD ﬂare and new onset IBD
are included (Roaccutane package insert, 2011; Wolverton,
2007).
Case 1: Is a 24 year old single female medical student who
was managed with isotretinoin for severe acne vulgaris in a
dose of 30 mg/day for 7 months, she started developing GIT
symptoms in the form of abdominal pain and diarrhea
2 months after initiating isotretinoin therapy, and in the last
2 months, the diarrhea was described as bloody and with mu-
cous. The patient had lost about 10 kg in that period, devel-
oped iron deﬁciency anemia, and had fatigue. She had no
signiﬁcant past medical history, and no family history of
IBD. There was no history of recent travel. A colonoscopy
and biopsy revealed a pancolitis, and she was given a diagnosis
of ulcerative colitis in October 2009, for which she was started
on 5 aminosalicylic acid, systemic steroids and an iron supple-
ment. Her dermatologist discontinued isotretinoin treatment,
the patient’s condition improved and systemic steroids werevier B.V. All rights reserved.
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acid. Currently she is in clinical remission.
Case 2: Is a 21 year old single female, not known to have
any previous medical problems and no family history of IBD,
was started on isotretinoin for hidradenitis suppurativa in a
dose of 40 mg/day. Four weeks after the initiation of therapy
with isotretinoin, she started having abdominal pain and a
bloody diarrhea. Her condition progressed in the following
months as she developed severe iron deﬁciency anemia
(hemoglobin dropping to 5.5 gm/dl), and had a signiﬁcant
weight loss of about 60 kg in 4 months. The patient discon-
tinued isotretnoin. Encapsulated endoscopy, colonoscopy
and a biopsy revealed a diagnosis of Crohn’s disease. She
was started on systemic steroids, mesalamine, and her severe
anemia was managed. Currently, she is maintained on adali-
lumab 40 mg subcutaneously every 2 weeks and is in clinical
remission. Table 1 shows a comparison between the two
cases.
2. Discussion
The most common side effect encountered with isotretinoin
use is xerosis of the skin and mucous membranes mainly lead-
ing to cheilitis. Some patients may have musculoskeletal aches
and pains, but there are a number of less commonly reported
side effects, and one such potentially serious side effect that
may be overlooked is aggravating or triggering IBD in suscep-
tible individuals (Roaccutane package insert, 2011; Wolverton,
2007).
How isotretinoin induces IBD is not clear, some proposed
mechanisms include ‘‘induction of ulceration and inﬂamma-
tion in the gut mucosa by inhibiting epithelial cell growth, dis-
ruption of the mucosal wall integrity by inhibiting glycoprotein
synthesis, and epithelial cell injury caused by stimulation of
killer T cells with a resultant inﬂammation’’ (Passier and
Srivastava, 2006; Reniers and Howard, 2001).
Upon reviewing the literature we have found several case
reports suggesting the association of isotretinoin use and
GIT manifestations including the development of IBD espe-
cially ulcerative colitis. Martin et al. was the ﬁrst to report a
case of proctosigmoiditis after isotretinoin exposure in 1987,
his case showed relapsing and remitting of the GIT symptoms
with reintroduction and withdrawal of isotretinoin, respec-
tively (Martin et al., 1987). Bharmal et al. documented a case
of worsening UC after isotretinoin treatment and his case
ended up having a subtotal colectomy and an ileostomy reﬂect-
ing the seriousness of such an adverse event (Bharmal and
Anderson, 2010). Papageorgiou et al. reported a case of UC
that developed after exposure to isotretinoin and remitted afterTable 1 Comparison between the two cases.
Age
Sex
Diagnosis
Isotretinoin dose
Isotretinoin duration of use
Onset of GIT symptoms after isotretinoin usethe drug was discontinued (Papageorgiou et al., 2009). Spada
et al. reported a case of pancolitis after starting treatment with
isotretinoin and complete resolution after discontinuation of
the medication (Spada et al., 2008). Passier et al. documented
3 cases of IBD that developed in previously healthy individuals
a few weeks after the discontinuation of isotretinoin, two of
which were ulcerative colitis and the third was a Crohn’s dis-
ease (Passier and Srivastava, 2006). Crockett et al. suggested
that UC not CD may be associated with isotretinoin exposure
and that higher doses increase the risk (Crockett et al., 2010).
Reniers et al. also reported a case of UC after discontinuation
of isotretinoin (Reniers and Howard, 2001), and Reddy et al.
reviewed 85 cases of IBD reported with the FDA in 4 years
from 1997 to 2000, and analyzed this association using the
Naranjo ADR probability scale, and found that ‘‘5% scored
‘highly probable’, 68% scored ‘probable’, 27% scored ‘possi-
ble’, and there were no ‘doubtful’ cases’’ (Reddy et al., 2006;
Bernstein et al., 2009; Naranjo et al., 1981).
Some of the reviewed reported cases of IBD showed
improvement or complete resolution of the symptoms after
withdrawal of isotretinoin, and ﬂare up upon rechallenge
(Reddy et al., 2006), others reported onset of GIT symptoms
after the completion of their isotretinoin course (Passier and
Srivastava, 2006; Reniers and Howard, 2001). Some of the
documented cases of IBD especially UC ended up with surgical
intervention in the form of a subtotal colectomy and ileostomy
(Bharmal and Anderson, 2010; Reniers and Howard, 2001).
Inﬂammatory bowel diseases (ulcerative colitis and Crohn’s
disease) are both immune mediated diseases of unknown etiol-
ogy but genetic predisposition and immune dysregulation
along with unknown environmental factors may play a role
in the pathogenesis (Reddy et al., 2006), the diseases tend to
be more diagnosed in young adults and late teenage years. This
age group is also more susceptible to acne vulgaris, which is a
very common skin problem affecting about 80% of adoles-
cents (Bharmal and Anderson, 2010). Bernstein et al. in his
argument against this association suggested that because of
the comparability of the age of onset of both entities, the devel-
opment of IBD in such patients could be coincidental
(Bernstein et al., 2009; Crockett et al., 2009). Also, some pa-
tients may actually have pre-existing subclinical IBD in which
isotretinoin may have acted as a trigger in unmasking the
symptoms in those predisposed individuals (Reddy et al.,
2006). The possibility of severe acne or inverse acne being an
extra-intestinal manifestation developing in these patients
prior to the onset of GIT symptoms is also plausible, as are
the well known extra-intestinal manifestations of erythema
nodosum and pyoderma gangrenosum (Tharkar, 2011;
Rolanda and Macedo, 2007).Case 1 Case 2
24 years 21 years
Female Female
Acne vulgaris Hidradenitis suppurativa
30 mg 40 mg
7 months 4 months
2 months 4 weeks
Inﬂammatory bowel disease and isotretinoin: An overlooked potential side effect? 75Godfrey reported his results in managing 4 patients with
IBD treated for severe acne with isotretinoin, from these 4
cases only one had a ﬂare of his IBD and the rest had success-
ful courses (Godfrey and James, 1990).
Margolis reported a case of Crohn’s disease in a patient
who has been exposed to doxycycline for treating acne
(Margolis et al., 2010 Dec). Our two cases had no previous his-
tory of exposure to tetracycline class of antibiotics.
3. Conclusion
The association between IBD and isotretinoin use is still a con-
troversial issue, just as it is with mood disorders, both have not
been adequately measured in any studies although there are
numerous case reports. So in prescribing isotretinoin a detailed
history including symptoms suggestive of IBD should be ob-
tained, and in previously healthy patients who develop GIT
symptoms while on isotretinoin, a referral to the gastroenterol-
ogist is advisable.
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